Actuate Therapeutics, Inc.
ACTU
$7.67
-$0.01-0.13%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.20M | 3.15M | 2.87M | 1.64M | 1.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.97M | 6.37M | 6.56M | 5.39M | 5.44M |
| Operating Income | -5.97M | -6.37M | -6.56M | -5.39M | -5.44M |
| Income Before Tax | -5.95M | -6.32M | -6.45M | -5.97M | -6.57M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.95M | -6.32M | -6.45M | -5.97M | -6.57M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.95M | -6.32M | -6.45M | -5.97M | -6.57M |
| EBIT | -5.97M | -6.37M | -6.56M | -5.39M | -5.44M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.30 | -0.32 | -0.33 | -0.55 | -4.20 |
| Normalized Basic EPS | -0.19 | -0.20 | -0.21 | -0.30 | -2.26 |
| EPS Diluted | -0.30 | -0.32 | -0.33 | -0.55 | -4.20 |
| Normalized Diluted EPS | -0.19 | -0.20 | -0.21 | -0.30 | -2.26 |
| Average Basic Shares Outstanding | 19.65M | 19.50M | 19.55M | 10.77M | 1.57M |
| Average Diluted Shares Outstanding | 19.65M | 19.50M | 19.55M | 10.77M | 1.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |